COSMIC-313: Final Results of Cabozantinib With Nivo/Ipi in Previously Untreated aRCC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Laurence Albiges, MD, PhD, of Institute Gustave Roussy, details the final results of COSMIC-313, highlighting the increased effectiveness of cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.

She also speaks to whether certain patient subgroups may derive the greatest benefit from the triplet combination, as well as how this triplet fits into clinical practice compared to other emerging triplet and sequential approaches.